Palo Alto Investors LP Takes Position in BioMarin Pharmaceutical Inc. $BMRN

Posted by Brian Himes on Aug 28th, 2026

Palo Alto Investors LP purchased a new position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 682,777 shares of the biotechnology company’s stock, valued at approximately $39,068,500,000. BioMarin Pharmaceutical comprises 5.4% of Palo Alto Investors LP’s investment portfolio, making the stock its 6th largest holding. Palo Alto Investors LP owned about 0.35% of BioMarin Pharmaceutical as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also added to or reduced their stakes in BMRN. CIBC Private Wealth Group LLC boosted its position in BioMarin Pharmaceutical by 38.2% during the 4th quarter. CIBC Private Wealth Group LLC now owns 648 shares of the biotechnology company’s stock worth $39,000 after buying an additional 179 shares during the period. Northwestern Mutual Investment Management Company LLC increased its position in BioMarin Pharmaceutical by 0.4% in the 4th quarter. Northwestern Mutual Investment Management Company LLC now owns 42,982 shares of the biotechnology company’s stock valued at $2,554,000 after acquiring an additional 183 shares during the period. Caerus Investment Advisors LLC increased its position in BioMarin Pharmaceutical by 2.8% in the 4th quarter. Caerus Investment Advisors LLC now owns 10,236 shares of the biotechnology company’s stock valued at $608,000 after acquiring an additional 278 shares during the period. Chicago Partners Investment Group LLC raised its stake in shares of BioMarin Pharmaceutical by 2.4% during the first quarter. Chicago Partners Investment Group LLC now owns 12,183 shares of the biotechnology company’s stock valued at $660,000 after acquiring an additional 290 shares during the last quarter. Finally, Parallel Advisors LLC raised its stake in shares of BioMarin Pharmaceutical by 62.2% during the third quarter. Parallel Advisors LLC now owns 769 shares of the biotechnology company’s stock valued at $42,000 after acquiring an additional 295 shares during the last quarter. Institutional investors own 98.71% of the company’s stock.

BioMarin Pharmaceutical Trading Down 0.5%

NASDAQ:BMRN opened at $65.29 on Friday. The firm’s fifty day moving average is $61.50 and its 200-day moving average is $58.10. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.32 and a current ratio of 2.39. BioMarin Pharmaceutical Inc. has a 52 week low of $49.26 and a 52 week high of $70.98. The firm has a market cap of $12.64 billion, a P/E ratio of 176.46, a P/E/G ratio of 0.47 and a beta of 0.24.

BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) last announced its earnings results on Thursday, August 6th. The biotechnology company reported $1.20 earnings per share for the quarter, topping analysts’ consensus estimates of $0.95 by $0.25. The business had revenue of $989.71 million during the quarter, compared to the consensus estimate of $932.03 million. BioMarin Pharmaceutical had a net margin of 2.14% and a return on equity of 5.32%. BioMarin Pharmaceutical’s quarterly revenue was up 20.0% on a year-over-year basis. During the same quarter last year, the firm earned $1.44 earnings per share. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. Equities analysts expect that BioMarin Pharmaceutical Inc. will post 4.1 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the stock. Sanford C. Bernstein reduced their price objective on shares of BioMarin Pharmaceutical from $94.00 to $82.00 and set an “outperform” rating on the stock in a research note on Tuesday, May 5th. Canaccord Genuity Group raised their target price on BioMarin Pharmaceutical from $111.00 to $114.00 and gave the stock a “buy” rating in a research report on Monday, August 10th. Royal Bank Of Canada cut their target price on BioMarin Pharmaceutical from $66.00 to $62.00 and set a “sector perform” rating on the stock in a report on Tuesday, July 7th. Citigroup upped their price target on BioMarin Pharmaceutical from $75.00 to $76.00 and gave the company a “buy” rating in a research report on Thursday, July 16th. Finally, Bank of America decreased their price target on BioMarin Pharmaceutical from $85.00 to $80.00 and set a “buy” rating for the company in a research note on Tuesday, May 19th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $88.79.

View Our Latest Stock Report on BMRN

BioMarin Pharmaceutical Company Profile

(Free Report)

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.